Clarify Pharma PLC Notice of AGM (3351K)

TIDMPSYC

RNS Number : 3351K

Clarify Pharma PLC

05 May 2022

Press Release

05 May 2022

Clarify Pharma PLC

("Clarify Pharma" or "the Company")

Notice of Annual General Meeting

Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, announces that it will hold its Annual General Meeting ('AGM') at 11:00am on Monday 30th May 2022 at the offices of Fladgate LLP, 16 Great Queen Street, London, England, WC2B 5DG.

Further details of the arrangements for this year's AGM are set out in the Notice of AGM, which together with the Form of Proxy, will be posted to shareholders today. The Notice of AGM will shortly also be available on the Company's website.

The directors of Clarify Pharma plc accept responsibility for this announcement.

For further information please contact:

 
 Clarify Pharma 
 Jon Bixby                             via Tancredi [phone] 
  Executive Chairman 
                                      ------------------------------ 
 First Sentinel 
                                      ------------------------------ 
 Corporate Adviser 
  Brian Stockbridge                    [phone] 
                                      ------------------------------ 
 Tennyson Securities 
                                      ------------------------------ 
 Corporate Broker 
  Peter Krens                          [phone] 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
                                      ------------------------------ 
 Media Relations 
  Catrina Daly 
  Emma Hodges 
  Salamander Davoudi                     [phone] 
                                         [phone] 
  [e-mail]        [phone] 
                                      ------------------------------ 
 

About Clarify Pharma PLC:

Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation. www.clarifypharma.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXUSOORUOUVRAR

(END) Dow Jones Newswires

May 05, 2022 02:01 ET (06:01 GMT)